ALTER1102
Regimen
- Experimental
- anlotinib
- Control
- placebo
Population
Recurrent or metastatic ESCC previously treated with chemotherapy
Key finding
mPFS 3.02 vs 1.41 mo (HR 0.46, 95% CI 0.32-0.66, p<0.001); OS not reached in abstract; grade 3-4 hypertension 16%
Source: PMID 33586360